Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Gynecologic 6Breast 5Thoracic 4Genitourinary 4Sarcoma 2Plasma cell 2Other hematologic neoplasm 2Head & Neck 2Dermatologic 2Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Leukemia, Myeloid, Acute 72Myelodysplastic Syndromes 34Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia, Biphenotypic, Acute 17Hematologic Neoplasms 14Burkitt Lymphoma 14Myeloproliferative Disorders 13Leukemia, Myelomonocytic, Chronic 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 7Myelodysplastic-Myeloproliferative Diseases 6Multiple Myeloma 6Lymphoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Primary Myelofibrosis 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Prostatic Neoplasms 3Neoplasm Metastasis 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Hairy Cell 3GATA2 Deficiency 3

Interventions

Specimen Handling 2Polymerase Chain Reaction 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Counseling 2Bupropion 2vactosertib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1temsirolimus 1tanespimycin 1sapanisertib 1relatlimab 1pertuzumab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine phosphate 1erdafitinib 1entinostat 1defactinib 1dabrafenib 1copanlisib 1capmatinib 1capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × Specimen Handling × Other hematologic neoplasm × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04314401 2026-05-13

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

Active not recruiting
1,600 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡